- Report
- January 2024
- 172 Pages
Global
From €1993EUR$2,190USD£1,693GBP
- Report
- December 2023
- 223 Pages
Global
€4546EUR$4,995USD£3,861GBP
- Report
- September 2021
- 105 Pages
Global
€3095EUR$3,400USD£2,628GBP
- Report
- June 2022
- 99 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- November 2021
- 844 Pages
Global
From €4551EUR$5,000USD£3,865GBP
- Report
- December 2023
- 279 Pages
Global
From €2351EUR$2,583USD£1,997GBP
€3359EUR$3,690USD£2,853GBP
- Report
- October 2022
- 229 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- September 2021
- 198 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- October 2023
Global
Serotonin is a neurotransmitter found in the central nervous system (CNS) that plays a role in regulating mood, appetite, sleep, and other bodily functions. It is a key target for drugs used to treat depression, anxiety, and other mental health disorders. Serotonin-based drugs are typically selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These drugs work by blocking the reuptake of serotonin, allowing it to remain active in the brain for longer periods of time.
The serotonin market is a subset of the larger CNS drug market, which is estimated to be worth billions of dollars. It is a highly competitive market, with many large pharmaceutical companies vying for market share. Companies in the serotonin market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more